Edition:
United States

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

24.68USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$24.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
74,828
52-wk High
$31.69
52-wk Low
$12.51

Chart for

About

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The... (more)

Overall

Beta: --
Market Cap(Mil.): $1,370.58
Shares Outstanding(Mil.): 55.94
Dividend: --
Yield (%): --

Financials

  APLS.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -1.17 -- --
ROI: -- 13.08 12.63
ROE: -- 14.80 14.50

BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy

* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment

* APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2

Dec 20 2017

BRIEF-Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

* APELLIS PHARMACEUTICALS EXPANDS MANAGEMENT TEAM, APPOINTS TIMOTHY SULLIVAN CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

Dec 19 2017

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 21 2017

Earnings vs. Estimates